Widely-cited paper co-authored by Dana-Farber Cancer Institute CEO retracted

"It is good to see this institution taking a harder stance against sloppy science," said Elisabeth Bik, a scientific whistleblower.

April 19, 2024 Check out STAT+

Sponsored By

Craig F. Walker/Globe Staff STAT+ | Dana-Farber retracts string of studies in systematic review of data integrity Dana-Farber CEO Laurie Glimcher, a co-author, requested the retraction from a prominent journal after questions were raised about images. By Angus Chen STAT+ | Cancer vaccine startup launches with $54 million, Spark veteran as CEO Corner Therapeutics' Series A round was led by Ziff Capital Partners, a little-known family office started by billionaire Dirk Ziff. By Allison DeAngelis U.S. to set limits on silica exposure first recommended half a century ago MSHA silica rule was decades in the making. Limits allowable airborne silica particles, offers health exams for affected miners. By Annalisa Merelli

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser